HER2 References

Original References:

1. Sarayeldin RM, Gupta I, Al-Hashimi I, et al. Gene expression and miRNAs profiling: Function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancers. 2019;11(5):646.
2. Furrer D, Paquet C, Jacob S, Diorio C. The human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive biomarker: Molecular insights into HER2 activation and diagnostic implications. In: Lemamy GJ, ed. Cancer Prognosis. IntechOpen Limited; 2018:11-22.
3. Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol. 2019;12(50):1-13.
4. Leyton JV. Improving receptor-mediated intracellular access and accumulation of antibody therapeutics–The tale of HER2. Antibodies (Basel). 2020;9(3):32.
5. Dieci MV, Miglietta F, Griguolo G, Guarneri V. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat Rev. 2020;88(102064):1-9.
6. Yan M, Achwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157-164.
7. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014;852748:1-9.
8. Meric-Bernstam F, Johnson AM, Dumbrava EEI, et al. Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033-2041.

Drug Table References:

1. Daiichi Sankyo Company, Ltd. ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use [package insert]. Revised August 2022.  https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true. Accessed October 18, 2022.
2. Genentech, Inc. HERCEPTIN (trastuzumab) for injection, for intravenous use [package insert]. Revised February 2021. www.gene.com/download/pdf/herceptin_prescribing.pdf. Accessed October 18, 2022.
3. Genentech, Inc. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [package insert]. Revised February 2019. www.gene.com/download/pdf/herceptin_hylecta_prescribing.pdf. Accessed October 18, 2022.
4. Celltrion, Inc. HERZUMA (trastuzumab-pkrb) for injection, for intravenous use [package insert]. Revised May 2019. www.herzuma.com/globalassets/herzuma-consumer/pdfs/herzuma-prescribing-information2.pdf. Accessed October 18, 2022.
5. Genentech, Inc. KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use [package insert]. Revised February 2022. www.gene.com/download/pdf/kadcyla_prescribing.pdf. Accessed October 18, 2022.
6. MacroGenics, Inc. MARGENZATM (margetuximab-cmkb) injection, for intravenous use [package insert]. Revised December 2020. www.margenza.com/pdf/prescribing-information.pdf. Accessed October 18, 2022.
7. Puma Biotechnology, Inc. NERLYNX (neratinib) tablets, for oral use [package insert]. Revised March 2022. https://nerlynxhcp.com/pdf/full-prescribing-information.pdf. Accessed October 18, 2022.
8. Mylan Pharmaceuticals Inc. OGIVRI (trastuzumab-dkst) for injection, for intravenous use [package insert]. Revised February 2021. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?type=display&setid=6b7938e6-14c7-4a65-9605-967542ecfb8f. Accessed October 18, 2022.
9. Organon LLC. ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use [package insert]. Revised June 2021. www.organon.com/product/usa/pi_circulars/o/ontruzant/Ontruzant-pi.pdf. Accessed October 18, 2022.
10. Genentech, Inc. PERJETA (pertuzumab) injection, for intravenous use [package insert]. Revised February 2021. www.gene.com/download/pdf/perjeta_prescribing.pdf. Accessed October 18, 2022.
11. Genentech, Inc. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use [package insert]. Revised June 2020. www.gene.com/download/pdf/phesgo_prescribing.pdf. Accessed October 18, 2022.
12. Pfizer Ireland Pharmaceuticals. TRAZIMERA (trastuzumab-qyyp) for injection, for intravenous use [package insert]. Revised November 2020. https://labeling.pfizer.com/ShowLabeling.aspx?id=12725. Accessed October 18, 2022.
13. Seagen Inc. TUKYSA (tucatinib) tablets, for oral use [package insert]. Revised February 2022. www.tukysahcp.com/pdf/TUKYSA_Full_Ltr_Master.pdf. Accessed October 18, 2022.
14. Novartis Pharmaceuticals Corporation. TYKERB (lapatinib) tablets, for oral use [package insert]. Revised March 2022. www.novartis.com/us-en/sites/novartis_us/files/tykerb.pdf. Accessed October 18, 2022.
15. Pfizer Laboratories Div Pfizer Inc. VIZIMPRO (dacomitinib) tablets, for oral use [package insert]. Revised December 2020. https://labeling.pfizer.com/ShowLabeling.aspx?id=11019. Accessed October 18, 2022.
16. Our Pipeline. AstraZeneca. Accessed October 18, 2022. www.astrazeneca.com/our-therapy-areas/pipeline.html.
17. Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa). ClinicalTrials.Gov. Accessed October 18, 2022. www.clinicaltrials.gov/ct2/show/NCT05306041.
18. Pipeline. Genentech. Accessed October 18, 2022. www.gene.com/medical-professionals/pipeline.
19. OP-1250 Pipeline. Olema. Accessed October 18, 2022. https://olema.com/pipeline/.
20. Product Development Portfolio. Roche. Accessed October 18, 2022. www.roche.com/solutions/pipeline.
21. Our Pipeline. Sanofi. Accessed October 18, 2022. www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline.
22. SHR6390. ClinicalTrials.gov. Accessed October 18, 2022. https://clinicaltrials.gov/ct2/results?cond=&term=SHR6390&cntry=&state=&city=&dist=.